Clinical Trials
12 trialsNCT07563595 2026-05-04
ELENI
iOMEDICO AG
Not yet recruiting
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT06309615 2025-05-29
PDxBRUTILITY
Precise Dx, Inc.
Not yet recruiting
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT05236257 2024-12-10
EPI VITRAKVI
Bayer
Completed
NCT05932290 2024-10-29
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT05565391 2024-05-21
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT05266430 2023-08-09
IL
Aura Biosciences
Terminated
NCT03501173 2023-07-25
GURC
Janssen Inc.
Completed
NCT02549222 2022-02-18
PIPER
Cerus Corporation
Completed
NCT03137264 2019-11-07
RADIANCE
AstraZeneca
Completed
NCT01254318 2016-11-02
TRAFIC
Merck Sharp & Dohme LLC
Completed